Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Giulio Metro, Massimo Di Maio


We agree with dr. Addeo and dr. Banna when they emphasize that the biology of non-small cell lung cancer (NSCLC) is complex, and that a single biomarker is probably not exhaustive in order to optimally predict (either positively or negatively) the potential efficacy of immune checkpoint inhibitors.